Business
Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development
CMV 7-month data shows all GMT measures at or above CMV seropositive baselines; pivotal Phase 3 study of at least 8,000 participants expected to begin in
About this update from Moderna, Inc.
[{"type":"text","content":"\nCMV 7-month data shows all GMT measures at or above CMV seropositive baselines; pivotal Phase 3 study of at least 8,000 participants expected to begin in 2021\n\nFirst interim analysis of Phase 1 RSV vaccine candidate (mRNA-1345) shows >11- fold increase in RSV neutralizing antibodies in younger adults (ages 18-49 years); both 50 μg and 100 μg dose levels generally well-tolerated\n\nPhase 1 clinical study of mRNA flu vaccine candidate expected to begin in 2021\n\nPhase 1 study evaluating HIV mRNA vaccines with novel strategy expected to begin in 2021\n\nCompany provided update on its COVID-19 Vaccine program on April 13\n\nVaccines Day to be held on Wednesday, April 14 at 8:00 a.m. ET\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is today hosting its second annual Vaccines Day, with presentations highlighting the advantages of mRNA vaccines. The Company is also announcing new positive interim Phase 1 data from its Respiratory Syncytial Virus (RSV) vaccine candidate (mRNA-1345) and new 7-month interim Phase 2 data from its cytomegalovirus (CMV) vaccine candidate. Building on its COVID-19 vaccine clinical development experience, the Company plans to invest resources and continue to leverage the power of its mRNA platform to accelerate the development of its mRNA vaccine pipeline.\n\n“Moderna has one of the world’s largest and most innovative vaccine development pipelines. We believe we have a unique opportunity to develop new vaccines against viruses hurting people around the world, at a pace that is radically different from what the industry has previously done,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are working to further increase our vaccine pipeline and accelerate these important programs. With our mRNA vaccines, we believe we have an opportunity to have a profound impact on human health.”\n\nThe vast majority of human viruses do not have a commercially available vaccine. This gap includes many long-known viruses causing a spectrum of long-term sequelae, such as cytomegalovirus (CMV) (discovered in 1956), Zika (1952) and Epstein-Barr virus (EBV, 1964), but also includes many emerging novel viruses. Since 1980, an average of two novel viruses that infect humans have been discovered each year. Exa...